Authors
Latest:
Addressing the Needs of Clinical Trial Sites in a Post-COVID-19 WorldRecognizing pre-pandemic pain points, such as patient engagement and protocol development, could lead to post-pandemic trial success.
Latest:
Effective regulatory strategies for rare diseaseIn the rare disease issue of New Medicines, Novel Insights from Parexel, experts and former regulators share insights for developing effective regulatory strategies earlier.
Latest:
Targeting Patient PopulationKeys to ensuring your clinical trials better reflect your target population.
Latest:
Budgets and Billing in Clinical Trials: DCT ConsiderationsCost strategies for medical device trials in the new era of digital health.
Latest:
Implementing a Gold Standard FSP Strategic PartnershipUse case explores the arrangement’s effectiveness in the biometrics setting.
Latest:
Precision Medicine in Clinical Trials: Adapting to the New Demands of Clinical Research TodayWebinar Date/Time: Thursday, May 25th, 2023 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST
Latest:
De-Risking Trials with Science-Driven OversightIdentifying the ‘significant six’ areas of clinical study conduct to mitigate risk.
Latest:
Post-Pandemic: An Argument for Protocol SimplicityWhat does the industry have to lose in pursuing a more straightforward path?
Latest:
AI/ML Approaches to Assisted Medical Writing—Part 2Following a discussion around summarization in Part 1, Part 2 discusses the method of pure abstraction in light of recent advances in deep learning and AI.
Latest:
Breathing New Life into Respiratory Clinical Trials with Digital BiomarkersIncreased data output from the use of devices can accelerate trials for this therapeutic area in need of new therapies.
Latest:
How to Measure Your Patient-Centric ImpactPractical suggestions for identifying what actionable insights have been impactful on clinical studies.
Latest:
How Reverse-Engineering Clinical Trials to Leverage the AI-based-Digital Twin Solution Solves for Many Current IssuesThese devices can help researchers identify data points that are not immediately available to researchers.
Latest:
Accelerating Innovation Adoption to Support Drug Development OperationsCharacterizing the long-term adoption experience of clinical technologies and capabilities—and what senior leaders can do to drive adoption within their walls.
Latest:
Expanding Conceptual Model of Disease into Conceptual Model of Patient Experience for Designing, Interpreting Medication EffectsA three-part framework for a more comprehensive conceptual model of patient experience data can provide a more rounded understanding of patient experiences in clinical trials and beyond.
Latest:
Modal Value Guided Clinical Trial Design Effectively Reduces Protocol AmendmentsAnalysis of 330,000 clinical trials calls for improved protocol design process.
Latest:
Accelerating Innovation Adoption to Support Drug Development OperationsCharacterizing the long-term adoption experience of clinical technologies and capabilities—and what senior leaders can do to drive adoption within their walls.
Latest:
Fortifying Defenses Pre-Patent CliffIntegrating artificial intelligence and advanced analytics throughout operations offers pharma companies a pathway to offset impending drug patent expirations.
Latest:
Medication Adherence Monitoring and Management:A Closer Look at the Role of Data Science and Understanding Patient BehaviorThe role of data science, how it can help us understand patient behavior, and why digital adherence solutions are the future.
Latest:
Introducing PALADINFirst-of-its-kind consortium dedicated to accelerating new medicines development through optimizing patient advocacy group—industry collaboration.
Latest:
The Current Status of European Research Related to COVID-19: The EUCROF PerspectiveSuccessful collaborations between Pharma/Biotech/Device industries and CROs will play a key role in an effective fight against the global COVID-19 pandemic.
Latest:
Enhancing Empowerment in Patient-Focused ResearchHow the inclusion of measures centered on net treatment benefit can drive an effective multifaceted approach.
Latest:
Establishing Metrics and Standardization for Non-CRF Data in EDCWhile Case Report Forms are a main contributor to collected data, non-CRF data such as core laboratory data and central imaging can be critical to any clinical study.
Latest:
Effective regulatory strategies for rare diseaseIn the rare disease issue of New Medicines, Novel Insights from Parexel, experts and former regulators share insights for developing effective regulatory strategies earlier.
Latest:
Beyond the Horizon: A New Era for Faster, Smarter Clinical TrialsCurrent industry trends align with the need for improved, fit for purpose technology.
Latest:
Employing the Power of Bayesian Methods to Expedite LearningBayesian methods bring flexibility and speed to clinical trial design and analysis, and with increased access to the necessary computational power, are transforming today’s clinical research.
Latest:
How Pharma Needs to Prepare for the Next PandemicMaster protocols helped accelerate research during the pandemic in the EU. How can US companies learn from this and start preparing master protocols now?
Latest:
Tailored Patient Involvement in Clinical TrialsThe approach of the Cancer Research UK Centre for Drug Development.
Latest:
How AI and Regulation are Reshaping the Future of Drug SafetyBalancing the emerging benefits of AI in pharmacovigilance with new responsibilities and demands from regulators in enhancing efficiency and safety.
Latest:
The Evolution of CRO and Sponsor RelationshipsExploring the 11 key ‘warning signs’ that could impact partnership success.
Latest:
A New Approach to Risk Balanced ContractingIn a complex world of global clinical trials where execution is riddled with uncertainty, how should sponsors and providers approach and achieve a balance of risk and reward?
